GSE37946HER2-enriched tumor initiating cell (HTIC) genomic predictor of response following neoadjuvant trastuzumab-based chemotherapy in HER2+ breast cancer
Homo sapiens
50 Downloadable Samples
Affymetrix Human Genome U133A Array (hgu133a)Submitter Supplied Information
Description
We identified a 17-gene Her2-enriched tumor initiating cell (HTIC) signature in MMTV-Her2/Neu mouse mammary TICs. Here, we show that patients with HTICS+ HER2+:ER tumors are more likely to achieve a pathologic complete response to trastuzumab-based neoadjuvant chemotherapy compared with HER2+:ER+ tumors.
PubMed ID
No associated PubMed ID
Publication Title
No associated publication
Total Samples
50
Submitter’s Institution
Authors
No associated authors
Source Repository
Samples
Show of 0 Total Samples
Filter
Add/Remove
Accession Code
Title
Age
Processing Information
Additional Metadata
Loading...
Some fields may be harmonized. Learn more